-
81.发明授权公开(公告)号：US07572795B2
公开(公告)日：2009-08-11
申请号：US11682331
申请日：2007-03-06
IPC分类号： C07D487/04 , A61K31/53 , A61P19/02 , A61P17/06 , A61P9/10
CPC分类号： C07D487/04
摘要： Compounds having the Formula (I), including pharmaceutically acceptable salts thereof, wherein at least one of X1, X2 or X3 is and any remaining X1, X2 or X3 is hydrogen, which are useful as kinase inhibitors, wherein R1, R2, R3, R4, R5, R6, A1, A2 and m are as described herein.
摘要翻译： 具有式（I）的化合物，包括其药学上可接受的盐，其中X 1，X 2或X 3中的至少一个为，并且任何其余的X 1，X 2或X 3为氢，其可用作激酶抑制剂，其中R 1，R 2，R 3， R4，R5，R6，A1，A2和m如本文所述。
-
82.发明申请公开(公告)号：US20090156555A1
公开(公告)日：2009-06-18
申请号：US12370081
申请日：2009-02-12
IPC分类号： A61K31/675 , C07F9/6561 , A61K31/53 , C07D487/04 , A61P29/00
CPC分类号： C07D487/04
摘要： Compounds having the Formula (I), including pharmaceutically acceptable salts thereof wherein at least one of X1, X2 or X3 is and any remaining X1, X2 or X3 is hydrogen, which are useful as kinase inhibitors, wherein R1, R2, R3, R4, R5, R6, A1, A2 and m are as described herein.
摘要翻译： 具有式（I）的化合物，包括其药学上可接受的盐，其中X 1，X 2或X 3中的至少一个为，并且任何其余的X 1，X 2或X 3为氢，其可用作激酶抑制剂，其中R 1，R 2，R 3，R 4 R5，R6，A1，A2和m如本文所述。
-
公开(公告)号：US20080004278A1
公开(公告)日：2008-01-03
申请号：US11832924
申请日：2007-08-02
申请人： Alaric Dyckman , Jagabandhu Das , Katerina Leftheris , Chunjian Liu , Robert Moquin , Stephen Wrobleski
发明人： Alaric Dyckman , Jagabandhu Das , Katerina Leftheris , Chunjian Liu , Robert Moquin , Stephen Wrobleski
IPC分类号： C07D231/10 , A61K31/4155 , A61K31/5377 , C07D403/02 , C07D413/02 , C07D231/56 , A61P29/00
CPC分类号： C07D231/14 , C07D231/12 , C07D231/40 , C07D401/12 , C07D413/12
摘要： The present invention provides pyrazole derived compounds of formula (I) useful for treating p38 kinase-associated conditions, where W, X, R1, R2, R3, R4, R5, R6 and m are as defined herein. The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention useful for treating p38 kinase-associated conditions, and methods of inhibiting the activity of p38 kinase in a mammal.
摘要翻译： 本发明提供了可用于治疗p38激酶相关病症的式（I）的吡唑衍生化合物，其中W，X，R 1，R 2，R 2， R 3，R 4，R 5，R 6和m如本文所定义。 本发明还涉及含有至少一种可用于治疗p38激酶相关病症的本发明化合物的药物组合物，以及抑制哺乳动物中p38激酶活性的方法。
-
公开(公告)号：US07253167B2
公开(公告)日：2007-08-07
申请号：US11170571
申请日：2005-06-29
IPC分类号： C07D487/14 , A61K31/53 , A61P11/00 , A61P19/02 , A61P37/06
CPC分类号： C07D487/14
摘要： The present invention relates to compounds having the formula, wherein, Q is optionally substituted aryl or heteroaryl, R1 is hydrogen or C1-4alkyl, and R2, R3, R4 and R5 are hydrogen or optional substituents as defined in the specification.
摘要翻译： 本发明涉及具有下式的化合物，其中Q为任选取代的芳基或杂芳基，R 1为氢或C 1-4烷基，R 1为氢或C 1-4烷基， R 2，R 3，R 4和R 5是氢或说明书中定义的任选的取代基。
-
公开(公告)号：US07160883B2
公开(公告)日：2007-01-09
申请号：US10420399
申请日：2003-04-22
IPC分类号： C07D487/04 , C07D413/08 , A61K31/53 , A61K31/5377 , A61P19/02 , A61P19/04 , A61P9/10
CPC分类号： C07D487/04
摘要： Compounds having the formula (I), and pharmaceutically acceptable salts, prodrugs, and solvates thereof, are useful as kinase inhibitors, wherein R1, R2, R3, R4, R5, R6, X and Z are as described in the specification.
-
公开(公告)号：US07034151B2
公开(公告)日：2006-04-25
申请号：US10773002
申请日：2004-02-05
申请人： Bang-Chi Chen , Rulin Zhao , Joseph Edward Sundeen , Katerina Leftheris , John Hynes , Stephen T. Wrobleski
发明人： Bang-Chi Chen , Rulin Zhao , Joseph Edward Sundeen , Katerina Leftheris , John Hynes , Stephen T. Wrobleski
IPC分类号： C07D487/04 , C07D253/07
CPC分类号： C07D487/04
摘要： An improved process for the preparation of certain pyrrolotriazine compounds is disclosed. The compounds exhibit utility as kinase inhibitors.
摘要翻译： 公开了制备某些吡咯并三嗪化合物的改进方法。 这些化合物表现出作为激酶抑制剂的作用。
-
公开(公告)号：US20060019928A1
公开(公告)日：2006-01-26
申请号：US11170571
申请日：2005-06-29
申请人： James Lin , Stephen Wrobleski , Chunjian Liu , Katerina Leftheris
发明人： James Lin , Stephen Wrobleski , Chunjian Liu , Katerina Leftheris
IPC分类号： A61K31/53 , A61K31/675 , C07D487/14
CPC分类号： C07D487/14
摘要： The present invention relates to compounds having the formula, wherein, Q is optionally substituted aryl or heteroaryl, R1 is hydrogen or C1-4alkyl, and R2, R3, R4 and R5 are hydrogen or optional substituents as defined in the specification.
摘要翻译： 本发明涉及具有下式的化合物，其中Q为任选取代的芳基或杂芳基，R 1为氢或C 1-4烷基，R 1为氢或C 1-4烷基， R 2，R 3，R 4和R 5是氢或说明书中定义的任选的取代基。
-
88.发明授权Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme 有权衍生自作为IMPDH酶抑制剂的胺核的化合物公开(公告)号：US06399773B1
公开(公告)日：2002-06-04
申请号：US09428432
申请日：1999-10-27
申请人： Chunjian Liu , T. G. Murali Dhar , Henry H. Gu , Edwin J. Iwanowicz , Katerina Leftheris , William J. Pitts
发明人： Chunjian Liu , T. G. Murali Dhar , Henry H. Gu , Edwin J. Iwanowicz , Katerina Leftheris , William J. Pitts
IPC分类号： C07D26528
CPC分类号： C07D231/12 , C07D233/56 , C07D249/08 , C07D263/32 , C07D263/48 , C07D413/12 , C07D413/14 , C07D417/12
摘要： The present invention discloses the identification of the novel inhibitors of IMPDH (inosine-5′-monophosphate dehydrogenase). The compounds and pharmaceutical compositions disclosed herein are useful in treating or preventing IMPDH mediated diseases, such as transplant rejection and autoimmune diseases.
摘要翻译： 本发明公开了IMPDH（肌苷-5'-单磷酸脱氢酶）的新型抑制剂的鉴定。 本文公开的化合物和药物组合物可用于治疗或预防IMPDH介导的疾病，例如移植排斥反应和自身免疫性疾病。
-
89.发明授权1,2,5-benzothiadiazepine-1,1-dioxides with n-2 imidazolylalkyl substituents 有权具有n-2个咪唑基烷基取代基的1,2,5-苯并噻二氮杂-1,1-二氧化物
公开(公告)号：US6156746A
公开(公告)日：2000-12-05
申请号：US354038
申请日：1999-07-15
IPC分类号： C07D417/06 , A61K31/551 , C07D419/14
CPC分类号： C07D417/06
摘要： Inhibition of farnesyl transferase, which is an enzyme involved in ras oncogene expression, is effected by compounds of the formula ##STR1## and their enantiomers, diastereomers, and their pharmaceutically acceptable salts, including prodrugs and solvates thereof.The compounds of formula I are useful in the treatment of a variety of cancers. In addition, the formula I compounds may also be useful in the treatment of diseases other than cancer.
摘要翻译： 抑制参与ras癌基因表达的酶的法呢基转移酶由下式的化合物及其对映异构体，非对映异构体及其药学上可接受的盐包括其前体药物和溶剂化物来实现。 式I化合物可用于治疗各种癌症。 此外，式I化合物还可用于治疗除癌症以外的疾病。
-
公开(公告)号：US08188272B2
公开(公告)日：2012-05-29
申请号：US12532330
申请日：2008-03-20
IPC分类号： C07D487/04 , C07D401/04 , A61K31/4188 , A61K31/53 , A61P19/02
CPC分类号： C07D487/04
摘要： Compounds having the formula (I), and enantiomers, and diastereomers, pharmaceutically-acceptable salts, thereof, [PLEASE INSERT CHEMICAL STRUCTURE HERE] (I) are useful as kinase modulators, including Btk modulation, wherein R1, R2, R4, Q, Y, A and D are as defined herein.
摘要翻译： 具有式（I）的化合物及其对映异构体和非对映体药学上可接受的盐可用作激酶调节剂，包括Btk调节，其中R1，R2，R4，Q， Y，A和D如本文所定义。
-
-
-
-
-
-
-
-
-
搜索结果
112 条记录 (耗时 0.067 秒)
